Conjubrook
Intended to relieve menopausal hot flashes to support comfort levels and target bone loss.
- Categories
- Women's Health · Menopause & HRT
- Active ingredient
- Conjugated Estrogens
- Route
- Oral use
- Form
- Tablet
- Strengths
- 0.625mg
Prescription and consultation requirements for Conjubrook vary by destination and are determined by the fulfilment partner.
Conjubrook details
- Conditions
- Menopausal Vasomotor Symptoms · Vulvar Atrophy
- Alternative names
- conjugated estrogens
- Therapeutic class
- Estrogen
- Pharmacological class
- Estrogen Derivative
- Known off-label uses
- postmenopausal osteoporosis prevention
- Contraindications
- unexplained genital bleeding; history of deep vein thrombosis; pregnancy
- Minor side effects
- nausea; headache; breast tenderness
- Moderate side effects
- fluid retention; weight changes; metrorrhagia
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Healing Pharma
- Onset Time
- 1–2 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Rifampin; Ketoconazole; St. John's Wort
- Age restrictions
- Approved for postmenopausal adult females.
Serious side effects
venous thromboembolism, requires immediate medical attention; endometrial carcinoma, requires immediate medical attention
Patient summary
intended to relieve menopausal hot flashes to support comfort levels and target bone loss.
Mechanism of action
Binds to estrogen receptors in target tissues, replacing depleted endogenous hormones to regulate vasodilation and bone metabolism.
Pregnancy and breastfeeding
TGA Category X: Strictly contraindicated. Can cause fetal damage. Breastfeeding: Not recommended.